The National Institutes of Allergy and Infectious Diseases (NIAID) is sponsoring a Phase 1 study evaluating transmission-blocking vaccine candidates Pfs25-EPA* and Pfs230-EPA, formulated with the adjuvant AS01, in Malian adult volunteers. This trial presents an opportunity to test, in a field setting, whether Pfs25 and/or Pfs230 delivered with AS01 can lead to better human responses than the same antigens formulated with Alhydrogel®.

The NIAID Laboratory of Malaria Immunology and Vaccinology will send blood samples from the trial to PATH reference centers for evaluation of vaccine-induced immune responses and functional activities. This effort will enable cross-product/cross-platform comparisons as appropriate and will also inform strategies for isolation of functional repertories from the vaccinated volunteers. The samples may be used to derive human monoclonal antibodies to Pfs25 and Pfs230.

ClinicalTrials.gov Identifier: NCT02942277

View detailed study record on clinicaltrials.gov

*ExoProtein A (EPA)